Clinical Trial Update: A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating long-term lorcaserin (BELVIQ) on major adverse cardiovascular events and conversion to type 2 diabetes in obese/overweight individuals …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Belviq (lorcaserin)

Snippet

Sponsor: Eisai Inc. | Conditions: Cardiovascular Disease, High Cardiovascular Risk | Phase 4 | Status: COMPLETED | Results posted: 2019-07-16